InMed Pharmaceuticals Inc.
INMAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Dec 22, 2021 |
| Roth Capital | maintain | Buy | Feb 16, 2021 |
Earnings History
Next report: Feb 16, 2027 · EPS est. $-944.44| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $-3.60 | $-94.44 | — | $300.0K |
| Sep 9, 2026 | $-14.30 | $-944.44 | $2.06B | — |
| May 11, 2026 | $-0.69 | $-944.44 | $1.3M | — |
| Feb 11, 2026 | $-0.51 | — | $1.1M | — |
| Nov 12, 2025 | $-0.44 | — | $1.3M | $1.8M |
| Sep 23, 2025 | $24.00 | — | $1.3M | $1.8M |
| May 12, 2025 | $-1.94 | — | $1.2M | $1.5M |
| Feb 12, 2025 | $-3.64 | — | $1.2M | $1.1M |
News
Shares expected to trade on Nasdaq under the ticker symbol "MTRI" commencing November 9, 2026 VANCOUVER, BC, Nov. 6, 2026 /PRNewswire/ -- InMed Pharmaceuticals Inc. (which has changed its name to Mentari Therapeutics, Inc.) (NASDAQ: INM) ("Mentari" or the "Company") today announced the completion of the previously disclosed merger between the Company and the privately held Mentari Therapeutics, Inc. ("pre-merger Mentari"). The combined company will continue to operate under the name Mentari Ther…
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, subject to the satisfaction or waiver of the remaining closing conditions under the agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Mer…
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, confirmed that, at its annual general and special meeting of shareholders held today (the "Meeting"), the matters put forward before shareholders for consideration and approval, as set out in th…
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its first quarter of fiscal 2027, ended September 30, 2026, and provided a corporate update. The Company's full financial statements and related MD&A for the quarter ended Septemb…
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, pursuant to the previously announced agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement") providing for the proposed merger (the "Merger") invo…
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, pursuant to the previously announced agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement") providing for the proposed merger (the "Merger") invo…
InMed Pharmaceuticals Inc. (NASDAQ: INM - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 15,876 shares, a decline of 48.4% from the August 31st total of 30,769 shares. Approximately 0.5% of the company's shares are short sold.
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the Com…
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com, www.s…
InMed Pharmaceuticals (NASDAQ: INM - Get Free Report) and Reviva Pharmaceuticals (NASDAQ: RVPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation. Institutional and Insider Ownership 20.1% of InMed